Quarterly ResultJul 28, 2026, 04:12 PM
NeoGenomics Q2 Revenue +11% to $202M; Raises FY26 Guidance
AI Summary
NeoGenomics reported strong second-quarter 2026 results, with total revenue increasing 11% year-over-year to $202 million and GAAP net income reaching $2 million. Adjusted EBITDA grew 36% to $14 million. The company also raised its full-year 2026 revenue and adjusted EBITDA guidance, reflecting consistent operating and financial performance. Key business developments included strengthening its capital structure through a $316 million convertible senior notes offering and finalizing a civil settlement with the Department of Justice.
Key Highlights
- Total revenue increased 11% YoY to $202 million in Q2 2026.
- Clinical services revenue grew 14%, with NGS revenue up 26%.
- GAAP net income was $2 million, including an $11 million gain on debt extinguishment.
- Adjusted EBITDA increased 36% to $14 million.
- Generated $20 million cash from operations, ending with $146 million cash.
- Raised full-year 2026 revenue guidance to $802 million - $806 million.
- Raised full-year 2026 Adjusted EBITDA guidance to $56 million - $58 million.
- Completed $316 million private offering of convertible senior notes due 2032.
- Finalized civil settlement with the Department of Justice.
Price Impact
More from NEO